An OpenAI researcher is stepping away from the ChatGPT maker to launch his own artificial-intelligence drug-discovery venture — and it doesn't even have a name yet.
According to The Next Web, the researcher, Miles Wang, is in talks to raise $200 million at a $2 billion valuation for the new company. Notably, the startup has no name and no product at this stage — investors would effectively be backing the founder and the premise rather than anything already built.
A separate report surfaced via Google News, from Briefs Finance, likewise frames the move as an ex-OpenAI researcher starting a $2 billion AI drug venture.
The eye-catching detail is the gap between the ambition and the substance. A $2 billion valuation is typically reserved for companies with revenue, technology, or a proven team. Here, the reporting describes a firm that is still just an idea attached to a founder with OpenAI on his résumé.
That pairing — an AI pedigree and drug discovery — is what commands the price. Investors have increasingly bet that AI can compress the slow, expensive process of finding new medicines, and talent leaving high-profile labs like OpenAI has become a magnet for capital.
Both sources are early reports, and the round is described as still in talks rather than closed, so the figures could shift.
Why it matters: The story is a vivid marker of how much investors will pay for AI talent and the promise of AI-driven medicine — enough to value a nameless, product-less company at $2 billion.